Telix Pharmaceuticals heads into its October 15 earnings report with the short score reversing off its recent peak, borrow conditions loosening, and a stock that gave back 3.8% over the week while analyst targets remain well above the current price.
The most notable shift since last week's note is that the short score has pulled back from its high. It peaked at 80.4 on September 23, the highest level in recent memory and the central tension flagged in the previous article. It has since retreated to 77.5 by September 29. That is still an elevated reading, but the directional change matters: the daily grind higher that characterised the prior week has reversed, and the score has now fallen for six consecutive sessions. Short interest itself has been essentially flat across the same period, sitting at 10.7% of free float on 36.1 million shares, marginally up on the week but well within the range it has occupied for the past month. The days-to-cover figure from the latest official settlement remains long at 18.5 days, keeping the structural squeeze potential in place.
The borrow market tells a meaningfully different story from a week ago. Availability has improved sharply, rising from around 123% of short interest in late September to 184% now, a near-50% jump over the week. Cost to borrow has also dropped, down 13% over seven days to 1.9% annually, its lowest level in several weeks. Both moves point in the same direction: the scramble for borrows that characterised mid-September has eased, and there is more room in the lending pool than there was at the previous peak. The 52-week high on utilisation was 70.5%, versus the current reading well below that. The lending market looks comfortably supplied rather than stressed.
The Street remains constructive at a distance. The consensus price target is AUD 24.14, against a close of AUD 16.15, implying roughly 49% upside if the analyst community's numbers are right. No recent changes to analyst ratings or targets are recorded, leaving a gap between Street optimism and a market that has re-rated the stock lower over recent months. Factor scores add nuance: EPS surprise ranks in the 76th percentile, suggesting the company has a track record of beating estimates, but EPS momentum over both 30 and 90 days ranks near the bottom of the universe (9th and 4th percentile respectively), pointing to a deteriorating revisions trend in the run-up to the print. The EV/EBITDA multiple of 67x and a trailing PE above 1,300x reflect a stock the market is still pricing on a long-dated growth story rather than current earnings.
One real-economy data point is worth carrying into the earnings context. Medicaid units reimbursed for Telix's drugs rose 37% against the same quarter a year earlier, based on CMS data covering the January 2026 period. This is not a measured leading indicator for Telix's reported revenue, so it cannot be read as predictive. But the scale of the year-on-year increase in reimbursement volumes gives a sense of where demand from the US government payer channel was running earlier in the year.
The insider register adds a small but genuine signal. CFO Darren Smith made an open-market purchase of 2,071 shares at AUD 9.66 on September 7, a modest transaction but executed at a price well below the current level and not under a pre-arranged trading plan. Earlier in the year, CEO Christian Behrenbruch bought nearly 68,000 shares across two days in late April at prices around AUD 14.50 to AUD 14.90. Both trades are in the money at the current price of AUD 16.15. Behrenbruch also holds a 6.4% stake according to the most recent institutional data, making him a substantive owner with skin in the game heading into the result.
The last earnings print delivered a roughly 7% one-day decline. With the short score still elevated despite pulling back, availability recovering, and the October 15 result two weeks away, the earnings reaction will be the clearest test of whether the bear case or the analyst community's target-price gap better reflects the underlying story.
See the live data behind this article on ORTEX.
Open TLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
